Enza Mule
Overview
Explore the profile of Enza Mule including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manti S, Giallongo A, Parisi G, Papale M, Mule E, Aloisio D, et al.
Pediatr Pulmonol
. 2023 Nov;
59(3):801-804.
PMID: 38014605
No abstract available.
2.
Giallongo A, Parisi G, Papale M, Manti S, Mule E, Aloisio D, et al.
Genes (Basel)
. 2023 Feb;
14(2).
PMID: 36833376
Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators represent targeted therapies directly acting on the CFTR channel. The triple therapy Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) has been demonstrated to improve lung function and...
3.
Manti S, Giallongo A, Pecora G, Parisi G, Papale M, Mule E, et al.
Pediatr Pulmonol
. 2023 Jan;
58(4):1085-1091.
PMID: 36593591
Background: Asthma guidelines have recommended continuing treatment with biologics during coronavirus disease 2019 (COVID-19) pandemic. However, a continuation of treatment with biologics in patients with severe acute respiratory syndrome coronavirus...
4.
Manti S, Giallongo A, Parisi G, Papale M, Mule E, Aloisio D, et al.
Eur Respir Rev
. 2022 Jul;
31(165).
PMID: 35896271
Background: is a common saprophytic fungus causing allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis (CF). The recommended first-line treatment for ABPA is oral steroids, followed by antifungal therapy....
5.
Papale M, Parisi G, Spicuzza L, Rotolo N, Mule E, Aloisio D, et al.
Acta Biomed
. 2021 May;
92(2):e2021164.
PMID: 33988138
Background And Aim: In patients with cystic fibrosis (CF) non-invasive ventilation (NIV) improves lung mechanics and gas exchange, and decreases the work of breathing. Domiciliary NIV is mainly used in...
6.
Manti S, Parisi G, Papale M, Mule E, Aloisio D, Rotolo N, et al.
Med Hypotheses
. 2021 Jan;
147:110481.
PMID: 33421691
Coronavirus disease 2019 (COVID-19) caused more than 52.775.271 million confirmed cases, 1.293.106 deaths, globally, and afflicted 208 countries, areas, or territories; and almost three months have passed since the World...
7.
Bongiovanni A, Manti S, Parisi G, Papale M, Mule E, Rotolo N, et al.
World J Gastroenterol
. 2020 Nov;
26(41):6322-6334.
PMID: 33244195
Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder in cystic fibrosis (CF), and based on various studies, its prevalence is elevated since childhood. There are several pathogenetic mechanisms on...
8.
Manti S, Parisi G, Papale M, Licari A, Chiappini E, Mule E, et al.
Pediatr Allergy Immunol
. 2020 Nov;
31 Suppl 26:20-22.
PMID: 33236425
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disease caused by Aspergillus induced hypersensitivity that occurs in immunocompetent but susceptible patients with asthma and/or cystic fibrosis (CF). In children, ABPA remains...
9.
Manti S, Parisi G, Papale M, Mule E, Aloisio D, Rotolo N, et al.
Front Med (Lausanne)
. 2020 Jun;
7:307.
PMID: 32582746
No abstract available.